Creativity Group for Borderline Personality Disorder

This study is currently recruiting participants.

Verified February 2011 by State University of New York - Upstate Medical University

First Received on April 26, 2011. Last Updated on April 27, 2011 History of Changes

Sponsor:	State University of New York - Upstate Medical University
Information provided by:	State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier:	NCT01343550

Purpose

The investigators hypothesize that a creativity skills group for Borderline Personality Disorder can reduce symptoms of BPD, depression, and anxiety.

Condition	Intervention	Phase
Borderline Personality Disorder	Other: creativity group	Phase 1

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Creativity Group for Borderline Personality Disorder

Resource links provided by NLM:

MedlinePlus related topics: Depression Personality Disorders

U.S. FDA Resources

Further study details as provided by State University of New York - Upstate Medical University:

Primary Outcome Measures:

Borderline Evaluation of Severity Over Time (BEST) [ Time Frame: baseline, 5th week, post-intervention (week 8) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Beck Depression Inventory (BDI) [ Time Frame: baseline, week 5, week 8 ] [ Designated as safety issue: No ]

Estimated Enrollment:	80
Study Start Date:	February 2011
Estimated Study Completion Date:	August 2011
Estimated Primary Completion Date:	August 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Creativity group for persons diagnosed with BPD	Other: creativity group This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.

Eligibility

Criteria

Inclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01343550

Contacts

Contact: Blake Bazel, M.S.	315-464-3144	bazelb@upstate.edu
Contact: Robbi Saletsky, Ph.D.	315-464-3165	saletsrt@upstate.edu

Locations

United States, New York
SUNY Upstate Medical University	Recruiting
Syracuse, New York, United States, 13210
Sub-Investigator: Blake Bazel, M.S.
Sub-Investigator: Robbi Saletsky, Ph.D.
Sub-Investigator: Roger Greenberg, Ph.D.
Principal Investigator: Robert Gregory, M.D.

Sponsors and Collaborators

State University of New York - Upstate Medical University

Investigators

Study Director:	Blake Bazel, M.S.	State University of New York - Upstate Medical University
Study Director:	Robbi Saletsky, Ph.D.	State University of New York - Upstate Medical University
Study Director:	Roger Greenberg, Ph.D.	State University of New York - Upstate Medical University

More Information

Publications:

Responsible Party:	Robert Gregory, M.D., SUNY Upstate Medical University
ClinicalTrials.gov Identifier:	NCT01343550 History of Changes
Other Study ID Numbers:	PHS6019
Study First Received:	April 26, 2011
Last Updated:	April 27, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by State University of New York - Upstate Medical University:

Borderline Personality Disorder
Borderline Personality
Borderline

Additional relevant MeSH terms:

Personality Disorders
Borderline Personality Disorder
Mental Disorders

ClinicalTrials.gov processed this record on May 23, 2012